These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 1669241)

  • 1. [Prolongation of the CAST study.Is it justified to consider another trial?].
    Lekieffre J; Kacet S; Caron J; Lacroix D; Libersa C
    Arch Mal Coeur Vaiss; 1991 Feb; 84 Spec No 2():71-4. PubMed ID: 1669241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Can sudden cardiac death be prevented by treatment with anti-arrhythmia drugs?].
    Zrenner B; Koller B; Rudolph W
    Herz; 1990 Apr; 15(2):90-102. PubMed ID: 2188895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [What is the latest in anti-arrhythmia therapy?].
    Gloor HO
    Schweiz Med Wochenschr; 1991 Nov; 121(47):1711-4. PubMed ID: 1720259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Class I anti-arrhythmia agents and prevention of sudden death following myocardial infarction].
    Boissel JP; Lièvre M; Rosenberg Y
    Arch Mal Coeur Vaiss; 1991 Feb; 84 Spec No 2():49-54. PubMed ID: 1669239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Late potentials, myocardial kinetics and ventricular vulnerability as markers of sudden death after myocardial infarct].
    D'Aulerio M; Gronda M; Prando MD; Occhetta E; Makmur J; Rossi L; Rossi P
    G Ital Cardiol; 1986 Feb; 16(2):114-26. PubMed ID: 3721103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of patients with risk of sudden death. The amiodarone example].
    Djian J
    Arch Mal Coeur Vaiss; 1994 Jan; 87(1 Spec No):67-74. PubMed ID: 7944868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
    Castelli G; Ciaccheri M; Cecchi F; Troiani V; Nannini M; Marconi P; Olivotto J; Montereggi A; Dolara A
    G Ital Cardiol; 1999 May; 29(5):514-23. PubMed ID: 10367218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of new anti-arrhythmia drugs after the CAST (Cardiac Arrhythmia Suppression Trial) study].
    Meinertz T; Zehender M; Hohnloser SH
    Z Kardiol; 1992; 81 Suppl 4():145-9. PubMed ID: 1290291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antiarrhythmic agents in the prevention of sudden cardiac death].
    Halawa B
    Pol Merkur Lekarski; 1999 Mar; 6(33):117-20. PubMed ID: 10365592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Course of ventricular arrhythmias following myocardial infarction. Results of a 2-year follow-up].
    Medvedowsky JL; Barnay C; Arnaud C; Bonet P
    Arch Mal Coeur Vaiss; 1984 Jul; 77(7):754-65. PubMed ID: 6433838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment after acute myocardial infarction: antiarrhythmic therapy and prophylaxis. Which drug for which patient?
    Bracchetti D; Naccarella F; Palmieri M; Fulvi M; Pavesi PC
    J Cardiovasc Pharmacol; 1989; 14 Suppl 9():S79-83. PubMed ID: 2483239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiarrhythmic agents: current situation].
    Bonhorst D
    Rev Port Cardiol; 1995 May; 14(5):421-9, 362. PubMed ID: 7654403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intermediary and substitution criteria in the development of anti-arrhythmia agents].
    Lièvre M; Leizorovicz A; Boissel JP
    Arch Mal Coeur Vaiss; 1991 Feb; 84 Spec No 2():27-33. PubMed ID: 1669237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Amiodarone and secondary prevention. The EMIAT study].
    Munoz A
    Arch Mal Coeur Vaiss; 1991 Feb; 84 Spec No 2():67-9. PubMed ID: 1726998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice.
    Kellen JC; Ettinger A; Todd L; Brezsnyak ML; Campion J; McBride R; Thomas S; Corum J; Schron E
    Am J Crit Care; 1996 Jan; 5(1):19-25. PubMed ID: 8680488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Spontaneous variability of ventricular arrhythmias in follow-up of anti-arrhythmia therapy].
    Schmidt G; Barthel P; Ulm K; Goedel-Meinen L; Baedeker W
    Herz; 1990 Feb; 15(1):11-20. PubMed ID: 1690167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratification for malignant arrhythmic events in patients with an acute myocardial infarction: role of an open infarct-related artery and the signal-averaged ECG.
    Hermosillo AG; Araya V; Casanova JM
    Coron Artery Dis; 1995 Dec; 6(12):973-83. PubMed ID: 8723020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Stratification of arrhythmia risk and therapeutic options in survivors of acute myocardial infarction].
    Arós Borau F; Loma-Osorio A; Torres Bosco A
    Rev Esp Cardiol; 1996 Mar; 49(3):157-65. PubMed ID: 8685518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Malignant ventricular arrhythmias in the subacute and late phases of myocardial infarction. Clinical arrhythmological characteristics and prognostic value].
    Proclemer A; Facchin D; Fresco C; Bernardi G; Fontanelli A; Feruglio GA
    G Ital Cardiol; 1990 May; 20(5):400-11. PubMed ID: 2210161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors affecting the all-cause death and sudden cardiac death rates of post myocardial infarction patients with low left ventricular ejection fraction.
    Dai SM; Zhang S; Chen KP; Hua W; Wang FZ; Chen X
    Chin Med J (Engl); 2009 Apr; 122(7):802-6. PubMed ID: 19493393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.